Indication

As monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2380
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
08 November 2021
Patient group submission deadline:
06 September 2021